Myriad Genetics, Inc. · NASDAQ:MYGN
Myriad Genetics — 40th Annual J.P. Morgan Health Care Conference (January 2022)
38 slides from Myriad Genetics's conference presentation, Jan 11, 2022
Slide 1: Illuminating the path to better health through genetic insights
Illuminating the path to better health through genetic insights 40th Annual J.P. Morgan Health Care Conference January 11, 2022 Paul J. Diaz President and CEO Myriad Genetics
Slide 2: Forward looking statements
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com 2 Forward looking statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based
Slide 3: Who we are, what we do, and why it matters
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com We advance health and wellbeing for all, empowering every individual by revealing the answers inside each of us. As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health, a
Slide 4: Empowering patients with answers and insights for better health
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com What’s my risk of breast cancer? How can I learn more about my baby's health during pregnancy? Why isn’t my antidepressant working? How can I beat this cancerous tumor? 3 million patients 2.1 million patients 1.7 million patients 150,00
Slide 5: Three focused businesses primed for growth
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Three focused businesses primed for growth 5 Operating Results Products Market* Business Oncology Genetic testing for cancer patients and companion diagnostic tests that work with corresponding drugs & treatments. Q3 ‘21 volume: 47,829
Slide 6: Transformation and growth strategy
Transformation and growth strategy
Slide 7: Strategic priorities
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Strategic priorities Innovation that improves clinical outcomes, ease of use, and access Enterprise capabilities to accelerate growth and scale to market opportunity Investing in tech-enabled commercial tools to drive engagement, improv
Slide 8: Executing our transformation plan, on track to accelerate growth
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Executing our transformation plan, on track to accelerate growth 2H CY20 CY21 CY22 8 Build culture of service excellence, prioritize innovation, reduce complexity and cost Reset the base ✓ Launched transformation plan ✓ Redefined brand
Slide 9: Mental Health
Mental Health
Slide 10: Addressing the U.S. mental health crisis and need for medication testing
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Addressing the U.S. mental health crisis and need for medication testing 10 Mark Verratti – President Q3 '21 revenue: $24.1M 1.7M+ people tested to date 7 clinical studies published Market Mental Health Business • GeneSight volumes grow
Slide 11: Commercial model driving lead generation, conversion in mental health
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Commercial model driving lead generation, conversion in mental health 11 Inside Sales cultivates broader base of leads – frees sales force to serve high potential accounts Field Sales works high potential, high revenue clinical leads Cu
Slide 12: Commercial model continues to drive new users
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Key drivers • Virtual patient testing capabilities • Online ordering • GeneSight@Home • Text and email messaging • Comprehensive mental health test, including ADHD 12 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 80,000 3Q 20 4Q 20
Slide 13: Women’s Health
Women’s Health
Slide 14: Serving healthcare providers and the women who rely on them
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Serving healthcare providers and the women who rely on them 14 Leading health and wellness with best-in- class genetic insights for women of all ancestries, assessing risk of cancer and offering prenatal testing solutions. Melissa Gonza
Slide 15: Key product enhancement – personalized breast cancer risk for all women
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Key product enhancement – personalized breast cancer risk for all women 15 • Only Myriad provides genetically-informed breast cancer risk assessment as part of a comprehensive panel, with equity in care for all patients • Closing the ga
Slide 16: Combined prenatal test simplifies and advances prenatal patient care
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Combined prenatal test simplifies and advances prenatal patient care • Early insight into recessive disease status • Eliminates unnecessary amniocentesis • Increased sensitivity for all pregnancies • Single maternal (no paternal) blood
Slide 17: Oncology
Oncology
Slide 18: Providing answers that guide cancer treatment decisions
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Providing answers that guide cancer treatment decisions 18 Business Faith Zaslavsky – President Q3 ‘21 revenue: $76.8M Market Oncology Genetic testing for cancer patients and companion diagnostic tests that work with corresponding drugs
Slide 19: Molecular diagnostics across the continuum of cancer care
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Molecular diagnostics across the continuum of cancer care 19 Precise Liquid Bx Precise Liquid Bx Therapeutic Selection Precise Liquid Bx MRD Working to expand portfolio into Liquid Bx therapy selection and Liquid Bx MRD Measurable Resid
Slide 20: A differentiated, comprehensive solution for advanced precision oncology
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com A differentiated, comprehensive solution for advanced precision oncology Helping providers determine the best treatment plan – clear, integrated, personalized • Partnering with Intermountain Healthcare and Illumina to become the only la
Slide 21: Rapidly growing ~$100M CDx business positioned for market expansion
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Rapidly growing ~ $100M CDx business positioned for market expansion 21 0 20 40 60 BRACAnalysis CDx MyChoice CDx CDx Revenue (Q3 trailing 4 quarters in $M) US/International Pharma (R&D) $48 $42 • Market leading expertise with BRACAnalys
Slide 22: Simplifying treatment decisions for men with prostate cancer
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Simplifying treatment decisions for men with prostate cancer 2211 January 2022 Key Growth Drivers • ~250K men diagnosed with prostate cancer / year, 2nd most common cancer • $900M total addressable market – only 25% penetrated • Medicar
Slide 23: Roadmap to expanding Myriad’s oncology portfolio
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Roadmap to expanding Myriad’s oncology portfolio 23 Launch Precise LBx Therapy Selection Launch Precise MRD Launch MyChoice CDx for multiple cancer types Launching Precise Oncology Solutions & Precise Tumor 2022 2023 2024 - 2025 Total $
Slide 24: Accelerating new commercial capabilities
Accelerating new commercial capabilities
Slide 25: Scaling our enterprise commercial and tech capabilities
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Scaling our enterprise commercial and tech capabilities 25 High potential, innovative products Product/channel management Brand management and marketing Competitive intelligence and market planning Sales operations and performance manag
Slide 26: Investing in direct-to-consumer demand generation – promising early results
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Investing in direct-to-consumer demand generation – promising early results 26 3-year goal >1 million qualified consumer leads for multiple products through patient-initiated testing Encounter Consider Inquire Tests Order reviewed and p
Slide 27: Customized end-to-end solutions for easy customer experience
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Customized end-to-end solutions for easy customer experience Myriad Complete™ Suite of services and workflow solutions • Simplifies genetic testing through patient and provider support at every step • Seamlessly integrates into clinic w
Slide 28: Stabilizing business and driving sustainable growth
Stabilizing business and driving sustainable growth
Slide 29: Myriad continues to stabilize business and improve operating and financial results
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Myriad continues to stabilize business and improve operating and financial results Financial highlights • Restored same-store growth • Improved gross margins and profitability through disciplined expense controls • Returned $400M to bal
Slide 30: Expect organic revenue growth to accelerate in 2022 going into 2023
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com MyRisk stabilization Expect organic revenue growth to accelerate in 2022 going into 2023 through improved sales and marketing execution, product and technology innovation 30 +4-5% +3-4% +2-3% Accelerating growth rate in ’24+9-12% Mental
Slide 31: Myriad Genetics 2022 financial guidance
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Myriad Genetics 2022 financial guidance 31 Guidance Key Assumptions Revenue* $670-$700 8% - 13% growth from 2021 baseline that excludes divested assets and positive cash collections from prior period orders Gross Margin % 70% - 72% Gros
Slide 32: Investment considerations: Myriad strengths and strategic advantages
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Significant market growth in focused business areas Best-in-class product quality Strong scalable commercial engine Size/scale within the industry Tech, data and research capabilities Industry leading operating margins & profitability I
Slide 33: Myriad Genetics Health. Illuminated.
of j \\ llyriad genetics Health. Illuminated.
Slide 34: Appendix – Third quarter 2021 operating and financial results
Appendix – Third quarter 2021 operating and financial results
Slide 35: Third quarter operating and financial results were strong, despite COVID-19 headwinds
©2021 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Third quarter operating and financial results were strong, despite COVID-19 headwinds and typical seasonal softness Total revenue of $167.3M increased 15% YOY Excluding the impact of the divested Vectra, RBM and myPath businesses, quart
Slide 36: Consolidated quarterly highlights
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Consolidated quarterly highlights Revenue, adjusted gross margin, adjusted operating income, adjusted EPS Quarter ended 36 In millions September 2021 June 2021 September 2020 Revenue $167.3 $189.4 $145.2 Sequential change (12%) 9% — Adj
Slide 37: Third quarter 2021 — revenue by product
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Third quarter 2021 — revenue by product Three months ended September 30 37 2021 2020 In millions Women’s Health Oncology Mental Health Other Total Women’s Health Oncology Mental Health Other Total % Change Hereditary cancer $35.5 $43.9
Slide 38: Revenue and test performance
©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com Revenue and test performance Year-over-year change September 2020-September 2021 38 Revenue Test Volume Hereditary cancer (1%) 0% Prenatal 42% 7% Tumor profiling 94% 33% Pharmacogenomics 103% 71% Overall company 15% 15% Overall company
Myriad Genetics — 40th Annual J.P. Morgan Health Care Conference (January 2022) on 6ix